Germany May End Free Skin Cancer Screenings for Millions

Germany May End Free Skin Cancer Screenings for Millions

Black and white photo of six men in suits and ties, each wearing spectacles, with the text "Colorectal Cancer: New Insights into a Preventable Disease" written underneath.

Nina Warken Is Cutting Costs in the Wrong Place

Germany May End Free Skin Cancer Screenings for Millions

Federal Health Minister Nina Warken plans to eliminate statutory skin cancer screenings as part of the government's austerity package—a move that is utterly counterproductive. While it may save money in the short term, it will prove far costlier in the long run.

Since 2008, Germans with statutory health insurance have been eligible for a skin cancer screening every two years starting at age 35. Warken argues that these screenings are conducted without specific cause and that the number of dangerous skin cancer cases has not declined. But this reasoning falls short. While it is true that reported cases have risen since the program's introduction, that does not undermine its purpose—it confirms it. Screenings are not meant to prevent cancer but to detect it early.

The critical point is that roughly 67 percent of skin cancer cases are now identified at an early stage, leading to lower treatment costs and better quality of life for patients. The numbers make it clear that cutting funding here will ultimately drive up expenses. In 2023 alone, around 27,000 people in Germany were diagnosed with melanoma, the deadliest form of skin cancer, while another 230,000 developed non-melanoma skin cancers.

This makes skin cancer the fifth most common cancer in Germany. While non-melanoma skin cancers are generally less aggressive, they can still have serious consequences, particularly in immunocompromised individuals. Melanoma, however, is far more likely to metastasize in advanced stages—and treating those metastases is expensive. Annual therapy with a drug like nivolumab costs around €76,000 per patient, whereas a single skin cancer screening costs less than €100.

Cutting back on screenings may save money now, but it simply shifts costs to far more expensive treatments later—while risking that early, treatable cases escalate into life-threatening illnesses. This is not sustainable health policy; it is a reckless step backward.

Neueste Nachrichten